(Q34973743)

5 August 2017

title

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor (English)

1 reference

5 August 2017

main subject

angiogenesis inhibitor

1 reference

Jérôme Giustiniani

8

0 references

Sylvie Giuriato

Sylvie Giuriato

13

0 references

Nabila Jabrane-Ferrat

Nabila Jabrane-Ferrat

2

0 references

Armand Bensussan

Armand Bensussan

22

0 references

Justin Teissie

Justin Teissié

20

0 references

Salem Chouaib

19

Salem Chouaib

1 reference

5 August 2017

Sophie Chabot

1

1 reference

5 August 2017

Karine Bigot

3

1 reference

5 August 2017

Julie Tabiasco

4

1 reference

5 August 2017

Alexandra Provost

5

1 reference

5 August 2017

Muriel Golzio

6

1 reference

5 August 2017

Muhammad Zaeem Noman

7

1 reference

5 August 2017

Elisabeth Bellard

9

1 reference

5 August 2017

Stéphanie Brayer

10

1 reference

5 August 2017

Maryse Aguerre-Girr

11

1 reference

5 August 2017

Fabienne Meggetto

12

1 reference

5 August 2017

François Malecaze

14

1 reference

5 August 2017

Stéphane Galiacy

15

1 reference

5 August 2017

Jean-Philippe Jaïs

16

1 reference

5 August 2017

Olivier Chose

17

1 reference

5 August 2017

Jean Kadouche

18

1 reference

5 August 2017

Marc Abitbol

21

1 reference

5 August 2017

Philippe Le Bouteiller

23

1 reference

5 August 2017

language of work or name

English

0 references

publication date

11 April 2011

1 reference

Journal of Experimental Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

208

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

973-986

1 reference

describes a project that uses

5 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3092350/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Adverse effects of anticancer agents that target the VEGF pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

CCR3 is a target for age-related macular degeneration diagnosis and therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Novel agents on the horizon for cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Tumor angiogenesis and molecular targets for therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

A role for VEGF as a negative regulator of pericyte function and vessel maturation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Modes of resistance to anti-angiogenic therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

VEGF-targeted therapy: mechanisms of anti-tumour activity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Interaction between bevacizumab and murine VEGF-A: a reassessment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Looking beyond Lucentis on the management of macular degeneration.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Intravital imaging and cell invasion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Development trends for monoclonal antibody cancer therapeutics.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Angiogenesis: an organizing principle for drug discovery?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Ocular drug development--future directions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Immune privilege and angiogenic privilege of the cornea

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Antiangiogenesis to treat cancer and intraocular neovascular disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Corneal avascularity is due to soluble VEGF receptor-1

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Ranibizumab for neovascular age-related macular degeneration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Angiogenesis in life, disease and medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Inhibition of pathologic retinal neovascularization by alpha-defensins

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Peptide mass fingerprinting by matrix-assisted laser desorption ionization mass spectrometry of proteins detected by immunostaining on nitrocellulose

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Pathology: cancer cells compress intratumour vessels.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Dissecting tumour pathophysiology using intravital microscopy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

8 July 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Is fractal geometry useful in medicine and biomedical sciences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Bevacizumab for corneal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

Antiangiogenic therapy: creating a unique "window" of opportunity

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092350

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

26 October 2018

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20100810

The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization

21 January 2018

1 reference

12 December 2020

Technology evaluation: bevacizumab, Genentech/Roche

1 reference

12 December 2020

Genentech discloses safety concerns over Avastin

1 reference

12 December 2020

Oxygen-induced retinopathy in the mouse

1 reference

12 December 2020

Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells

1 reference

12 December 2020

Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth

1 reference

12 December 2020

Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis

1 reference

12 December 2020

Optimizing the delivery of cancer drugs that block angiogenesis

1 reference

12 December 2020

Identifiers

DOI

10.1084/JEM.20100810

1 reference

5 August 2017

0 references

1 reference

5 August 2017

1 reference